Xeris Biopharma Holdings, Inc. (XERS)
8.75
+0.01
(+0.11%)
USD |
NASDAQ |
Aug 25, 16:00
8.75
0.00 (0.00%)
After-Hours: 19:59
Xeris Biopharma Holdings Total Liabilities (Quarterly) : 421.64M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 421.64M |
| March 31, 2026 | 379.00M |
| December 31, 2025 | 379.25M |
| September 30, 2025 | 371.05M |
| June 30, 2025 | 353.99M |
| March 31, 2025 | 350.58M |
| December 31, 2024 | 358.77M |
| September 30, 2024 | 349.43M |
| June 30, 2024 | 351.02M |
| March 31, 2024 | 345.79M |
| December 31, 2023 | 347.58M |
| September 30, 2023 | 323.92M |
| June 30, 2023 | 315.14M |
| March 31, 2023 | 291.31M |
| December 31, 2022 | 299.45M |
| September 30, 2022 | 247.98M |
| June 30, 2022 | 244.67M |
| March 31, 2022 | 241.17M |
| Date | Value |
|---|---|
| December 31, 2021 | 209.49M |
| September 30, 2021 | 133.72M |
| June 30, 2021 | 131.61M |
| March 31, 2021 | 123.25M |
| December 31, 2020 | 125.39M |
| September 30, 2020 | 156.05M |
| June 30, 2020 | 141.43M |
| March 31, 2020 | 89.39M |
| December 31, 2019 | 94.55M |
| September 30, 2019 | 84.44M |
| June 30, 2019 | 59.10M |
| March 31, 2019 | 53.87M |
| December 31, 2018 | 44.62M |
| September 30, 2018 | 42.47M |
| June 30, 2018 | 28.92M |
| March 31, 2018 | 28.71M |
| December 31, 2017 | 4.95M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Zevra Therapeutics, Inc. | 85.06M |
| Aclaris Therapeutics, Inc. | 55.11M |
| ANI Pharmaceuticals, Inc. | 896.90M |
| Corcept Therapeutics, Inc. | 182.93M |
| Veru, Inc. | 8.651M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 411.90M |
| Shareholders Equity (Quarterly) | -9.734M |
| Debt to Equity Ratio | -29.74 |
| Current Ratio | 1.449 |
| Net Debt Paydown Yield | -0.30% |